乳腺MRI与Kaiser评分在BI-RADS 0和4类病变中的诊断价值:与病理及随访对照
本研究为单中心回顾性研究,纳入99例常规影像(乳腺X线和超声)诊断为BI-RADS 0或4类后行乳腺MRI的患者,以病理或至少12个月随访为参考标准。MRI BI-RADS以>4为截断值,敏感度60.6%、特异度100%。结论认为Kaiser评分在BI-RADS 0或4类病变中诊断准确性优异,可辅助病变分层,但活检决策仍需结合临床与影像综合判断。
要点
- BI-RADS 0或4类病变行乳腺MRI时,Kaiser评分>5提示恶性可能性高,敏感度97%。
- MRI BI-RADS>4时特异度达100%,但敏感度仅60.6%,需警惕漏诊。
- Kaiser评分可辅助BI-RADS分层,但不能单独替代活检决策。
核心结论
- 对于常规影像诊断为BI-RADS 0或4类的乳腺病变,Kaiser评分诊断准确性优异,可与MRI BI-RADS联合用于病变分层,但活检决策应基于临床与影像综合评估。
研究设计与样本
- 单中心回顾性研究,纳入2022年9月至2024年4月间99例因常规乳腺影像(乳腺X线和超声)结果不确定或可疑(BI-RADS 0或4类)而行乳腺MRI的患者。
- 参考标准为超声或乳腺X线引导下活检的病理结果,或至少12个月的临床随访。
- 患者按病理或随访结局分为良性组和恶性组进行比较。
诊断标准与关键数值
- MRI BI-RADS以>4为截断值预测恶性,AUC=0.878(95%CI:0.805-0.950,p<0.001),敏感度60.6%(95%CI:42.1%-77.1%),特异度100%(95%CI:94.6%-100.0%)。
- 多因素logistic回归中,较高Kaiser评分(OR=4.25,p<0.001)和年龄较大(OR=1.16,p=0.041)与恶性概率升高相关,初潮年龄较大与恶性概率降低相关(OR=0.347,p=0.030)。
临床应用与阅片要点
- 对常规影像BI-RADS 0或4类病变行乳腺MRI时,可计算Kaiser评分辅助预判恶性风险,评分>5者恶性可能性高。
- MRI BI-RADS>4时特异度极高,但敏感度有限,阅片时不宜仅凭BI-RADS≤4排除恶性。
- 活检决策仍需结合临床和影像综合判断,Kaiser评分可作为分层参考而非独立决策依据。
局限性
- 单中心回顾性研究,样本量99例,结论外推需谨慎。
- 参考标准部分依赖至少12个月随访而非全部病理证实,可能存在验证偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Breast cancer is the most frequently diagnosed cancer type in women, and early detection and treatment significantly improve survival rates. In conventional imaging methods (mammography and ultrasound), lesions classified as BI-RADS 0 or 4 often lead to a high rate of unnecessary biopsies, resulting in both superfluous invasive procedures for patients and increased costs for the healthcare system. The aim of our study is to investigate the diagnostic validity of the Kaiser score in predicting malignancy in patients who underwent breast MRI following inconclusive or suspicious findings (BI-RADS 0 or 4) on conventional imaging, based on pathology results or clinical follow-up.
MATERIALS AND METHODS: Between September 2022 and April 2024, 99 patients who underwent breast MRI due to inconclusive results from conventional breast imaging methods (mammography and breast ultrasound) or the detection of suspicious findings (BI-RADS 0 or 4), and who had either histopathological evaluation following biopsy under US or MG guidance or were followed for at least 12 months, were included in this single-center retrospective study. The 99 patients included in the study were divided into two groups based on histopathology or follow-up outcomes (benign lesion group and malignant lesion group). Comparisons were made between these two groups.
RESULTS: When comparing benign and malignant groups, statistically significant differences were observed for age (p < 0,001), age at menarche (p = 0,004), breastfeeding status (p = 0,009), menopausal status (p = 0,017), and use of hormone replacement therapy (p = 0,036). MRI BI-RADS (p < 0,001) and Kaiser scores (p < 0,001) were notably higher in the malignant group. Kaiser score was identified as the strongest diagnostic predictor of malignancy (AUC = 0,977, 95 % CI: 0.955-0.999; p < 0,001). Using a cut-off value of Kaiser score > 5, the sensitivity and specificity were 97 % (95 % CI: 84.2 %-99.9 %) and 87.9 % (95 % CI: 77.5 %-94.6 %), respectively. The MRI BI-RADS ranked second with a cut-off value > 4 (AUC = 0.878, 95 % CI: 0.805-0.950; p < 0.001); at this threshold, the sensitivity and specificity were 60.6 % (95 % CI: 42.1 %-77.1 %) and 100 % (95 % CI: 94.6 %-100.0 %), respectively. In multivariable logistic regression, higher Kaiser score (OR = 4.25, p < 0.001) and older age (OR = 1.16, p = 0.041) were associated with higher odds of malignancy, whereas older age at menarche was associated with lower odds (OR = 0.347, p = 0.030).
CONCLUSION: For breast lesions classified as BI-RADS 0 or 4 on conventional imaging, the Kaiser score provides excellent diagnostic accuracy and may support lesion stratification when used with MRI BI-RADS assessment; biopsy decisions should remain based on integrated clinical and imaging findings.
引用
- Zengin E, Şimşir BD, Çevik ME, et al. Diagnostic value of breast MRI and Kaiser score in BIRADS 0 and 4 lesions compared with histopathology and follow-up. Eur J Radiol. 2026. PMID: 42913345. doi:10.1016/j.ejrad.2026.113310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。